Those are smallish, non-randomized trials comparing to historical data. I think the statistically significant data on monthly vs PRN for both Avastin and Lucentis presented in the randomized CATT trial easily trumps those:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.